Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares Outstanding
Ratios

Acro Biomedical (ACBM) EBIAT (2016 - 2025)

Acro Biomedical has reported EBIAT over the past 10 years, most recently at $42526.0 for Q4 2025.

  • Quarterly results put EBIAT at $42526.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was -$101146.0 (down 139.13% YoY), and the annual figure for FY2025 was -$101146.0, down 139.13%.
  • EBIAT for Q4 2025 was $42526.0 at Acro Biomedical, up from -$117809.0 in the prior quarter.
  • Over the last five years, EBIAT for ACBM hit a ceiling of $42526.0 in Q4 2025 and a floor of -$4.0 million in Q3 2022.
  • Median EBIAT over the past 5 years was -$456248.0 (2021), compared with a mean of -$1.6 million.
  • Biggest five-year swings in EBIAT: crashed 6503.69% in 2022 and later surged 498.44% in 2025.
  • Acro Biomedical's EBIAT stood at -$3.9 million in 2021, then dropped by 2.12% to -$3.9 million in 2022, then soared by 99.54% to -$18240.0 in 2023, then surged by 41.49% to -$10673.0 in 2024, then surged by 498.44% to $42526.0 in 2025.
  • The last three reported values for EBIAT were $42526.0 (Q4 2025), -$117809.0 (Q3 2025), and -$15562.0 (Q2 2025) per Business Quant data.